{"entity":{"id":"nct04373369","kind":"trial","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Vorolanib and Atezolizumab in Extensive-stage small-cell lung cancer, run by Washington University School of Medicine, recorded as terminated on the registry.","summary":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT04373369 by Washington University School of Medicine, with 11 participants recorded, started 2020-10-07 and due to reach its primary completion in 2022-08-18. Interventions recorded: Vorolanib, Atezolizumab. Conditions recorded: Extensive-stage Small Cell Lung Cancer.\n\nLinked to the drug Vorolanib because the registry names it among its interventions and Extensive-stage small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04373369","url":"https://clinicaltrials.gov/study/NCT04373369"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["vorolanib","atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04373369","phase":"2","setting":"A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC","sponsor":"Washington University School of Medicine","started":"2020-10-07","startedType":"actual","yearReported":2023,"enrolled":11,"enrolledBasis":"registry","outcomes":[{"endpoint":"Kaplan Meier Estimate of Progression-free Survival (PFS) at 6 Months","primary":true,"unit":"%","arms":[{"name":"Vorolanib + Atezolizumab","n":11,"value":27.3,"note":"90% CI 8.9 to 49.8; Figures from the ClinicalTrials.gov results section (first posted 2023-06-02), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04373369?tab=results"},{"endpoint":"Median Overall Survival","unit":"months","arms":[{"name":"Vorolanib + Atezolizumab","n":11,"value":14.6,"note":"90% CI 5.1 to 16.7; Figures from the ClinicalTrials.gov results section (first posted 2023-06-02), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04373369?tab=results"}]},"route":"/trials/nct04373369/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/"}]}}